Search

Your search keyword '"Segara, Davendra"' showing total 29 results
Start Over Author "Segara, Davendra" Publication Year Range Last 10 years
29 results on '"Segara, Davendra"'

1. Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid Metabolism

Author

Filipe, Elysse C., primary, Velayuthar, Sipiththa, additional, Philp, Ashleigh, additional, Nobis, Max, additional, Latham, Sharissa L., additional, Parker, Amelia L., additional, Murphy, Kendelle J., additional, Wyllie, Kaitlin, additional, Major, Gretel S., additional, Contreras, Osvaldo, additional, Mok, Ellie T. Y., additional, Enriquez, Ronaldo F., additional, McGowan, Suzanne, additional, Feher, Kristen, additional, Quek, Lake‐Ee, additional, Hancock, Sarah E., additional, Yam, Michelle, additional, Tran, Emmi, additional, Setargew, Yordanos F. I., additional, Skhinas, Joanna N., additional, Chitty, Jessica L., additional, Phimmachanh, Monica, additional, Han, Jeremy Z. R., additional, Cadell, Antonia L., additional, Papanicolaou, Michael, additional, Mahmodi, Hadi, additional, Kiedik, Beata, additional, Junankar, Simon, additional, Ross, Samuel E., additional, Lam, Natasha, additional, Coulson, Rhiannon, additional, Yang, Jessica, additional, Zaratzian, Anaiis, additional, Da Silva, Andrew M., additional, Tayao, Michael, additional, Chin, Ian L., additional, Cazet, Aurélie, additional, Kansara, Maya, additional, Segara, Davendra, additional, Parker, Andrew, additional, Hoy, Andrew J., additional, Harvey, Richard P., additional, Bogdanovic, Ozren, additional, Timpson, Paul, additional, Croucher, David R., additional, Lim, Elgene, additional, Swarbrick, Alexander, additional, Holst, Jeff, additional, Turner, Nigel, additional, Choi, Yu Suk, additional, Kabakova, Irina V., additional, Philp, Andrew, additional, and Cox, Thomas R., additional

Published
2024
Full Text
View/download PDF

2. The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology: Introduction and Overview

Author

Field, Andrew S., Raymond, Wendy A., Rickard, Mary T., Arnold, Lauren, Brachtel, Elena F., Chaiwun, Benjaporn, Chen, Lan, Chong, P. Y., Di Bonito, Luigi, Hoda, Rana S., Kurtycz, Daniel F. I., Lee, Andrew H. S., Lim, Elgene, Ljung, Britt-Marie, Michelow, Pamela, Osamura, Robert Y., Pinamonti, Maurizio, Sauer, Torill, Segara, Davendra, Tse, Gary M., Vielh, Philippe, Schmitt, Fernando, Field, Andrew S., editor, Raymond, Wendy A., editor, and Schmitt, Fernando, editor

Published
2020
Full Text
View/download PDF

3. Clinical Management

Author

Cohen-Hallaleh, Ruben, Rickard, Mary T., Lim, Elgene, Raymond, Wendy A., Segara, Davendra, Arnold, Lauren, Lee, Andrew H. S., Schmitt, Fernando, Field, Andrew S., Field, Andrew S., editor, Raymond, Wendy A., editor, and Schmitt, Fernando, editor

Published
2020
Full Text
View/download PDF

4. A single-cell and spatially resolved atlas of human breast cancers

Author

Wu, Sunny Z., Al-Eryani, Ghamdan, Roden, Daniel Lee, Junankar, Simon, Harvey, Kate, Andersson, Alma, Thennavan, Aatish, Wang, Chenfei, Torpy, James R., Bartonicek, Nenad, Wang, Taopeng, Larsson, Ludvig, Kaczorowski, Dominik, Weisenfeld, Neil I., Uytingco, Cedric R., Chew, Jennifer G., Bent, Zachary W., Chan, Chia-Ling, Gnanasambandapillai, Vikkitharan, Dutertre, Charles-Antoine, Gluch, Laurence, Hui, Mun N., Beith, Jane, Parker, Andrew, Robbins, Elizabeth, Segara, Davendra, Cooper, Caroline, Mak, Cindy, Chan, Belinda, Warrier, Sanjay, Ginhoux, Florent, Millar, Ewan, Powell, Joseph E., Williams, Stephen R., Liu, X. Shirley, O’Toole, Sandra, Lim, Elgene, Lundeberg, Joakim, Perou, Charles M., and Swarbrick, Alexander

Published
2021
Full Text
View/download PDF

6. Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis

Author

Wu, Sunny Z., Roden, Daniel L., Al-Eryani, Ghamdan, Bartonicek, Nenad, Harvey, Kate, Cazet, Aurélie S., Chan, Chia-Ling, Junankar, Simon, Hui, Mun N., Millar, Ewan A., Beretov, Julia, Horvath, Lisa, Joshua, Anthony M., Stricker, Phillip, Wilmott, James S., Quek, Camelia, Long, Georgina V., Scolyer, Richard A., Yeung, Bertrand Z., Segara, Davendra, Mak, Cindy, Warrier, Sanjay, Powell, Joseph E., O’Toole, Sandra, Lim, Elgene, and Swarbrick, Alexander

Published
2021
Full Text
View/download PDF

7. Stromal cell diversity associated with immune evasion in human triple‐negative breast cancer

Author

Wu, Sunny Z, Roden, Daniel L, Wang, Chenfei, Holliday, Holly, Harvey, Kate, Cazet, Aurélie S, Murphy, Kendelle J, Pereira, Brooke, Al‐Eryani, Ghamdan, Bartonicek, Nenad, Hou, Rui, Torpy, James R, Junankar, Simon, Chan, Chia‐Ling, Lam, Chuan En, Hui, Mun N, Gluch, Laurence, Beith, Jane, Parker, Andrew, Robbins, Elizabeth, Segara, Davendra, Mak, Cindy, Cooper, Caroline, Warrier, Sanjay, Forrest, Alistair, Powell, Joseph, O'Toole, Sandra, Cox, Thomas R, Timpson, Paul, Lim, Elgene, Liu, X Shirley, and Swarbrick, Alexander

Published
2020
Full Text
View/download PDF

9. Data from Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer

Author

Peters, Amelia A., primary, Buchanan, Grant, primary, Ricciardelli, Carmela, primary, Bianco-Miotto, Tina, primary, Centenera, Margaret M., primary, Harris, Jonathan M., primary, Jindal, Shalini, primary, Segara, Davendra, primary, Jia, Li, primary, Moore, Nicole L., primary, Henshall, Susan M., primary, Birrell, Stephen N., primary, Coetzee, Gerhard A., primary, Sutherland, Robert L., primary, Butler, Lisa M., primary, and Tilley, Wayne D., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Tables 1-3 from Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer

Author

Peters, Amelia A., primary, Buchanan, Grant, primary, Ricciardelli, Carmela, primary, Bianco-Miotto, Tina, primary, Centenera, Margaret M., primary, Harris, Jonathan M., primary, Jindal, Shalini, primary, Segara, Davendra, primary, Jia, Li, primary, Moore, Nicole L., primary, Henshall, Susan M., primary, Birrell, Stephen N., primary, Coetzee, Gerhard A., primary, Sutherland, Robert L., primary, Butler, Lisa M., primary, and Tilley, Wayne D., primary

Published
2023
Full Text
View/download PDF

11. Abstract OT2-01-10: WinPro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early-stage hormone receptor-positive breast cancer

Author

Downton, Teesha, primary, Segara, Davendra, additional, Ong, Andrew, additional, Bingham, Janne, additional, Carson, Emma-Kate, additional, Chen, Julia, additional, Middleton, Kate, additional, Lindeman, Geoffrey, additional, Parker, Andrew, additional, and Lim, Elgene, additional

Published
2023
Full Text
View/download PDF

12. Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status

Author

Downton,Teesha, Zhou,Fiona, Segara,Davendra, Jeselsohn,Rinath, and Lim,Elgene

Subjects
Drug Design, Development and Therapy
Abstract

Teesha Downton,1,2 Fiona Zhou,1,2 Davendra Segara,1 Rinath Jeselsohn,3,* Elgene Lim1,2,* 1Garvan Institute of Medical Research, Sydney, NSW, Australia; 2School of Clinical Medicine, St Vincent’s Healthcare Clinical Campus, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia; 3Dana-Farber Cancer Institute, Boston, MA, USA*These authors contributed equally to this workCorrespondence: Elgene Lim, Tel +61 2 9355 5600, Fax +61 2 9355 5602, Email e.lim@garvan.org.auAbstract: Several endocrine therapies are currently available for the treatment of estrogen receptor (ER) positive breast cancer, but the clinical benefit of these agents is limited by endocrine therapy drug resistance. A common mechanism of endocrine therapy resistance is ESR1 mutations. The first-generation selective estrogen receptor degrader (SERD) fulvestrant has activity against ESR1 mutant tumors but requires intramuscular injection and has poor bioavailability that precludes optimal drug dosing. This led to the development of second-generation SERDs which are potent and have improved oral bioavailability and pharmacokinetics. Several of these oral SERDs are now in phase III trials in both the early and advanced ER positive breast cancer settings. This review summarizes the background of oral SERD development, the current status and future perspectives.Keywords: selective estrogen receptor degraders, breast cancer, estrogen receptor

Published
2022

15. Abstract PS18-17: Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer

Author

Portman, Neil, primary, Milioli, Heloisa, additional, Alexandrou, Sarah, additional, Coulson, Rhiannon, additional, Yong, Aliza, additional, Fernandez, Kristine, additional, Chia, KeeMing, additional, Halilovic, Ensar, additional, Segara, Davendra, additional, Parker, Andrew, additional, Haupt, Sue, additional, Haupt, Ygal, additional, Tilley, Wayne, additional, Swarbrick, Alex, additional, Caldon, Liz, additional, and Lim, Elgene, additional

Published
2021
Full Text
View/download PDF

16. Abstract OT-09-07: Winpro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer

Author

Lau, Brandon, primary, Segara, Davendra, additional, Ong, Andrew, additional, Bingham, Janne, additional, Kiely, Belinda, additional, Carson, Emma-Kate, additional, Chen, Julia, additional, Mak, Cindy, additional, Warrier, Sanjay, additional, Hui, Mun, additional, Middleton, Kate, additional, Parker, Andrew, additional, Mann, Bruce, additional, Lindeman, Geoffrey, additional, Tilley, Wayne, additional, and Lim, Elgene, additional

Published
2021
Full Text
View/download PDF

17. MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer

Author

Portman, Neil, primary, Milioli, Heloisa H., additional, Alexandrou, Sarah, additional, Coulson, Rhiannon, additional, Yong, Aliza, additional, Fernandez, Kristine J., additional, Chia, Kee Ming, additional, Segara, Davendra, additional, Parker, Andrew, additional, Haupt, Sue, additional, Haupt, Ygal, additional, Tilley, Wayne D., additional, Swarbrick, Alex, additional, Caldon, C. Elizabeth, additional, and Lim, Elgene, additional

Published
2020
Full Text
View/download PDF

18. Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis

Author

Wu, Sunny Z., primary, Roden, Daniel L., additional, Al-Eryani, Ghamdan, additional, Bartonicek, Nenad, additional, Harvey, Kate, additional, Cazet, Aurelie S., additional, Chan, Chia-Ling, additional, Junankar, Simon, additional, Hui, Mun N., additional, Millar, Ewan, additional, Beretov, Julia, additional, Horvath, Lisa, additional, Joshua, Anthony M., additional, Stricker, Phillip, additional, Wilmott, James S., additional, Quek, Camelia, additional, Long, Georgina V., additional, Scolyer, Richard A., additional, Yeung, Bertrand Z., additional, Segara, Davendra, additional, Mak, Cindy, additional, Warrier, Sanjay, additional, Powell, Joseph, additional, O'Toole, Sandra, additional, Lim, Elgene, additional, and Swarbrick, Alexander, additional

Published
2020
Full Text
View/download PDF

19. Single-cell analysis reveals diverse stromal subsets associated with immune evasion in triple-negative breast cancer

Author

Wu, Sunny Z., primary, Roden, Daniel L., additional, Wang, Chenfei, additional, Holliday, Holly, additional, Harvey, Kate, additional, Cazet, Aurélie S., additional, Murphy, Kendelle J., additional, Pereira, Brooke, additional, Al-Eryani, Ghamdan, additional, Bartonicek, Nenad, additional, Hou, Rui, additional, Torpy, James R., additional, Junankar, Simon, additional, Chan, Chia-Ling, additional, Lam, Eric, additional, Hui, Mun N., additional, Gluch, Laurence, additional, Beith, Jane, additional, Parker, Andrew, additional, Robbins, Elizabeth, additional, Segara, Davendra, additional, Mak, Cindy, additional, Cooper, Caroline, additional, Warrier, Sanjay, additional, Forrest, Alistair, additional, Powell, Joseph, additional, O’Toole, Sandra, additional, Cox, Thomas R., additional, Timpson, Paul, additional, Lim, Elgene, additional, Liu, X. Shirley, additional, and Swarbrick, Alexander, additional

Published
2020
Full Text
View/download PDF

20. Window of opportunity treatment in breast cancer

Author

Chen, Julia, primary, Easwaralingam, Neshanth, additional, Warrier, Sanjay, additional, Ong, Andrew, additional, Carson, Emma‐Kate, additional, Mak, Cindy, additional, Snook, Kylie, additional, Middleton, Kate, additional, Parker, Andrew, additional, Palmieri, Carlo, additional, Spillane, Andrew, additional, Mann, G. Bruce, additional, Lim, Elgene, additional, and Segara, Davendra, additional

Published
2019
Full Text
View/download PDF

21. Targeting AR in endocrine-resistant breast cancer

Author

Chia, KeeMing, primary, Milioli, Heloisa, additional, Portman, Neil, additional, Laven-Law, Geraldine, additional, Coulson, Rhiannon, additional, Yong, Aliza, additional, Segara, Davendra, additional, Parker, Andrew, additional, Caldon, Catherine E, additional, Deng, Niantao, additional, Swarbrick, Alexander, additional, Tilley, Wayne D, additional, Hickey, Theresa E, additional, and Lim, Elgene, additional

Published
2019
Full Text
View/download PDF

22. The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer

Author

Chen, Julia, primary, Carson, Emma, additional, Segara, Davendra, additional, Parker, Andrew, additional, O'Toole, Sandra, additional, Coates, Alan, additional, Mann, Bruce, additional, Lindeman, Geoffrey, additional, Tilley, Wayne, additional, and Lim, Elgene, additional

Published
2019
Full Text
View/download PDF

23. Non-canonical AR activity facilitates endocrine resistance in breast cancer

Author

Chia, KeeMing, primary, Milioli, Heloisa, additional, Portman, Neil, additional, Laven-Law, Geraldine, additional, Coulson, Rhiannon, additional, Yong, Aliza, additional, Segara, Davendra, additional, Parker, Andrew, additional, Caldon, Catherine E, additional, Deng, Niantao, additional, Swarbrick, Alexander, additional, Tilley, Wayne D, additional, Hickey, Theresa E, additional, and Lim, Elgene, additional

Published
2019
Full Text
View/download PDF

24. The International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy Cytopathology

Author

Field, Andrew S., primary, Raymond, Wendy A., additional, Rickard, Mary, additional, Arnold, Lauren, additional, Brachtel, Elena F., additional, Chaiwun, Benjaporn, additional, Chen, Lan, additional, Di Bonito, Luigi, additional, Kurtycz, Daniel F.I., additional, Lee, Andrew H.S., additional, Lim, Elgene, additional, Ljung, Britt-Marie, additional, Michelow, Pamela M., additional, Osamura, Robert Y., additional, Pinamonti, Maurizio , additional, Sauer, Torill, additional, Segara, Davendra, additional, Tse, Gary, additional, Vielh, Philippe, additional, Chong, Phek Y., additional, and Schmitt, Fernando, additional

Published
2019
Full Text
View/download PDF

25. Window of opportunity treatment in breast cancer.

Author

Chen, Julia, Easwaralingam, Neshanth, Warrier, Sanjay, Ong, Andrew, Carson, Emma‐Kate, Mak, Cindy, Snook, Kylie, Middleton, Kate, Parker, Andrew, Palmieri, Carlo, Spillane, Andrew, Mann, G. Bruce, Lim, Elgene, and Segara, Davendra

Subjects
HORMONE receptor positive breast cancer, BREAST cancer, CANCER treatment, CANCER hormone therapy, BIOMARKERS, PREOPERATIVE period
Abstract

Window of opportunity therapies, which involve short‐term administration of systemic therapy between cancer diagnosis and surgery, have raised significant interest in recent years as a mean of assessing the sensitivity of a patient's cancer to therapy prior to surgery. There is now compelling evidence that in patients with early stage hormone‐receptor positive breast cancer, a 2‐week preoperative treatment with standard hormone therapies in a preoperative window period provides important prognostic information, which in turn helps to aid decision‐making regarding treatment options. Changes in short‐term biomarker endpoints such as cell proliferation measured by Ki‐67 can act as surrogate markers of long‐term outcomes. Paired tissues obtained pre‐ and post‐investigational treatment, without having to subject the patient to additional biopsies, can then be used to conduct translational research to investigate predictive biomarkers and pharmacodynamics. In this review, we will examine the utility and challenges of window of opportunities therapies in breast cancer in the current literature, and the current Australian and international trial landscape in this clinical space. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

27. Non-canonical AR activity facilitates endocrine resistance in breast cancer.

Author

KeeMing Chia, Milioli, Heloisa, Portman, Neil, Laven-Law, Geraldine, Coulson, Rhiannon, Yong, Aliza, Segara, Davendra, Parker, Andrew, Caldon, Catherine E., Niantao Deng, Swarbrick, Alexander, Tilley, Wayne D., Hickey, Theresa E., and Lim, Elgene

Subjects
ANDROGEN receptors, BREAST cancer, GENE expression profiling, CELL lines
Abstract

The role of androgen receptor (AR) in endocrine-resistant breast cancer is controversial and clinical trials targeting AR with an AR antagonist (e.g., e nzalutamide) have been initiated. Here, we investigated the consequence of AR antagonism using in vitro and in vivo models of endocrine resistance. AR antagonism in MCF7-derived tamoxifen-resistant (TamR) and long-term estrogen-deprived breast cancer cell lines were achieved using siRNA-mediated knockdown or pharmacological inhibition with enzalutamide. The efficacy of enzalutamide was further assessed in vivo in an estrogen-independent endocrineresistant patient-derived xenograft (PDX) model. Knockdown of AR inhibited the growth of the endocrine-resistant cell line models. Microarray gene expression profiling of the TamR cells following AR knockdown revealed perturbations in proliferative signaling pathways upregulated in endocrine resistance. AR loss also increased some canonical ER signaling events and restored sensitivity of TamR cells to tamoxifen. In contrast, enzalutamide did not recapitulate the effect of AR knockdown in vitro, even though it inhibited canonical AR signaling, which suggests that it is the non-canonical AR activity that facilitated endocrine resistance. Enzalutamide had demonstrable efficacy in inhibiting AR activity in vivo but did not affect the growth of the endocrine-resistant PDX model. Our findings implicate non-canonical AR activity in facilitating an endocrine-resistant phenotype in breast cancer. Unlike canonical AR signaling which is inhibited by enzalutamide, non-canonical AR activity is not effectively antagonized by enzalutamide, and this has important implications in the design of future AR-targeted clinical trials in endocrine-resistant breast cancer. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

29. Appendicitis diagnosed on positron emission tomography scan: an 'incidentalitis'.

Author

Pennington, Thomas E., Enoch, Jade F., and Segara, Davendra

Subjects
POSITRON emission tomography, APPENDICITIS
Abstract

The article presents a case study of a 28-year-old female presented with mast cell sarcoma of the right ilium and local nodal involvement. It discussed the laparoscopic appendicectomy of patient results of Histopathological examination that focused acute perforated appendicitis of submucosal mast cells in absence of tumorous aggregation.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results